Nebulized Opioids Use in COPD

Pamela A. Foral, Mark A. Malesker, Guillermo Huerta, Daniel E. Hilleman

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Objective: To evaluate the role of nebulized opioids in COPD. Methods: A MEDLINE search was completed to obtain pertinent clinical literature. Key search terms included the following: nebulizer, opioids, COPD, dyspnea, morphine, and hydromorphone. Results: Currently, the evidence in the literature is lacking regarding placebo-controlled studies to support nebulized morphine for the relief of dyspnea in patients with COPD. The studies reviewed varied considerably in the dose, opioid used, administration schedule, and methodology. One study found improved exercise capacity in 11 patients not reproducible in a larger sample, and another study found benefit in 54 terminal patients. All other studies found no benefit. Conclusions: The recently published Global Initiative for Lung Disease guidelines have specifically stated that opioids are contraindicated in COPD management due to the potential respiratory depression and worsening hypercapnia. Nebulized opioids should be discouraged, as current data do not support their use.

Original languageEnglish
Pages (from-to)691-694
Number of pages4
JournalChest
Volume125
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Chronic Obstructive Pulmonary Disease
Opioid Analgesics
Dyspnea
Morphine
Hydromorphone
Hypercapnia
Nebulizers and Vaporizers
MEDLINE
Respiratory Insufficiency
Lung Diseases
Appointments and Schedules
Placebos
Guidelines
Exercise

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Nebulized Opioids Use in COPD. / Foral, Pamela A.; Malesker, Mark A.; Huerta, Guillermo; Hilleman, Daniel E.

In: Chest, Vol. 125, No. 2, 02.2004, p. 691-694.

Research output: Contribution to journalReview article

Foral, Pamela A. ; Malesker, Mark A. ; Huerta, Guillermo ; Hilleman, Daniel E. / Nebulized Opioids Use in COPD. In: Chest. 2004 ; Vol. 125, No. 2. pp. 691-694.
@article{3db7c7ef225e4fe8ba0f03d49ec3c487,
title = "Nebulized Opioids Use in COPD",
abstract = "Objective: To evaluate the role of nebulized opioids in COPD. Methods: A MEDLINE search was completed to obtain pertinent clinical literature. Key search terms included the following: nebulizer, opioids, COPD, dyspnea, morphine, and hydromorphone. Results: Currently, the evidence in the literature is lacking regarding placebo-controlled studies to support nebulized morphine for the relief of dyspnea in patients with COPD. The studies reviewed varied considerably in the dose, opioid used, administration schedule, and methodology. One study found improved exercise capacity in 11 patients not reproducible in a larger sample, and another study found benefit in 54 terminal patients. All other studies found no benefit. Conclusions: The recently published Global Initiative for Lung Disease guidelines have specifically stated that opioids are contraindicated in COPD management due to the potential respiratory depression and worsening hypercapnia. Nebulized opioids should be discouraged, as current data do not support their use.",
author = "Foral, {Pamela A.} and Malesker, {Mark A.} and Guillermo Huerta and Hilleman, {Daniel E.}",
year = "2004",
month = "2",
doi = "10.1378/chest.125.2.691",
language = "English",
volume = "125",
pages = "691--694",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - Nebulized Opioids Use in COPD

AU - Foral, Pamela A.

AU - Malesker, Mark A.

AU - Huerta, Guillermo

AU - Hilleman, Daniel E.

PY - 2004/2

Y1 - 2004/2

N2 - Objective: To evaluate the role of nebulized opioids in COPD. Methods: A MEDLINE search was completed to obtain pertinent clinical literature. Key search terms included the following: nebulizer, opioids, COPD, dyspnea, morphine, and hydromorphone. Results: Currently, the evidence in the literature is lacking regarding placebo-controlled studies to support nebulized morphine for the relief of dyspnea in patients with COPD. The studies reviewed varied considerably in the dose, opioid used, administration schedule, and methodology. One study found improved exercise capacity in 11 patients not reproducible in a larger sample, and another study found benefit in 54 terminal patients. All other studies found no benefit. Conclusions: The recently published Global Initiative for Lung Disease guidelines have specifically stated that opioids are contraindicated in COPD management due to the potential respiratory depression and worsening hypercapnia. Nebulized opioids should be discouraged, as current data do not support their use.

AB - Objective: To evaluate the role of nebulized opioids in COPD. Methods: A MEDLINE search was completed to obtain pertinent clinical literature. Key search terms included the following: nebulizer, opioids, COPD, dyspnea, morphine, and hydromorphone. Results: Currently, the evidence in the literature is lacking regarding placebo-controlled studies to support nebulized morphine for the relief of dyspnea in patients with COPD. The studies reviewed varied considerably in the dose, opioid used, administration schedule, and methodology. One study found improved exercise capacity in 11 patients not reproducible in a larger sample, and another study found benefit in 54 terminal patients. All other studies found no benefit. Conclusions: The recently published Global Initiative for Lung Disease guidelines have specifically stated that opioids are contraindicated in COPD management due to the potential respiratory depression and worsening hypercapnia. Nebulized opioids should be discouraged, as current data do not support their use.

UR - http://www.scopus.com/inward/record.url?scp=1242329138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242329138&partnerID=8YFLogxK

U2 - 10.1378/chest.125.2.691

DO - 10.1378/chest.125.2.691

M3 - Review article

VL - 125

SP - 691

EP - 694

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -